Sanjivani Paranteral Ltd's subsidiary commences commercial production of new IV Fluid Infusion Plant

Sanjivani Paranteral Limited's subsidiary, SPL Infusion Pvt. Ltd., has commenced commercial production at its newly established IV Fluid Infusion Plant in Pune, Maharashtra, with effect from 6th September 2025, after receiving the requisite manufacturing license from the concerned authorities.

The Pune location is strategically important, offering proximity to leading pharmaceutical clusters and hospitals, supported by robust infrastructure and strong supply-chain connectivity, enabling the Company to efficiently cater to both domestic and export markets.

The facility has been designed with a dual focus on efficiency and sustainability. It houses state-of-the-art plant and machinery incorporating the latest technology, which is expected to enhance product quality, improve consistency. In addition, installation of solar panels will add eco-friendly electricity supply, lower electricity consumption and cut long-term operating costs.

This development marks a pivotal milestone in the Company's growth journey, as it expands manufacturing scale, establishes a new revenue vertical, and further strengthens its position in the healthcare and pharmaceutical manufacturing sector.

Shares of Sanjivani Paranteral Limited was last trading in BSE at Rs. 245.80 as compared to the previous close of Rs. 247.65. The total number of shares traded during the day was 16857 in over 169 trades.

The stock hit an intraday high of Rs. 256.00 and intraday low of 241.30. The net turnover during the day was Rs. 4190669.00.

Source : Equity Bulls

Keywords

INE860D01013 SanjivaniParanteral Pharmaceuticals SPLInfusion CommecialProduction IVFluidInfusionPlant